What will Iridium shareholders receive in the Rocket Lab deal?

Each Iridium share converts into $27.00 in cash plus Rocket Lab common stock at an exchange ratio that depends on Rocket Lab's 10-day VWAP before closing. The ratio is 0.4000 at or below $67.50, 0.2400 at or above $112.50, and $27.00 divided by the VWAP in between. At the $69.33 VWAP used in the filing, the ratio is 0.3894, or about 41.3 million new Rocket Lab shares in total.

How will the transaction be financed, and what does it cost?

The deal relies on a $3.6 billion 364-day bridge facility from Deutsche Bank and Wells Fargo, with an effective rate of about 8.0%. Rocket Lab says it intends to replace it with permanent financing on better terms, but those terms are not yet determinable. Each 0.125% change in the rate moves annual interest expense by about $4.6 million on the full balance.

How does the deal affect Rocket Lab's financial profile?

On a pro forma basis, the combined company shows larger losses than Rocket Lab alone, driven mainly by about $312 million of FY2025 interest expense and about $286 million of amortization and stock compensation. Pro forma EPS is -$0.36 for FY2025 and -$0.23 for six months 2026, and cash drops to roughly $1.0 billion. The filing excludes any expected synergies, so these figures show the financing and accounting effects rather than a forecast of operating performance.

What could still change, and what are the main risks?

The purchase price allocation is preliminary and could change materially, and each $1 move in Rocket Lab's share price above $112.50 changes consideration by about $25 million, while each $1 below $67.50 changes it by about $42 million. The transaction needs Iridium stockholder approval, regulatory clearances, and an effective Form S-4. The tax-free reorganization treatment depends on the cash-to-stock mix, and the bridge borrowings could fall if Iridium debt amendments are completed. Iridium's July 2026 Aireon acquisition added debt that is not in these figures.

RKLB 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed August 13, 2026. Cited figures are marked; the original filing is the authoritative source.

Rocket Lab (RKLB) filed this Form 8-K on August 13, 2026 to furnish financial information tied to its pending acquisition of Iridium Communications (IRDM), agreed June 28, 2026.

Under the Merger Agreement, Iridium holders would receive $27.00^a in cash plus Rocket Lab stock at a floating exchange ratio: 0.4000 shares if Rocket Lab's 10-day VWAP is at or below $67.50, 0.2400 at or above $112.50, and $27.00 divided by the VWAP in between. Using the 10-day VWAP ending August 7, 2026 of $69.33, the exchange ratio is 0.3894, implying about 41.3 million new Rocket Lab shares and an estimated total purchase consideration of roughly $7.59 billion. The filing itself contains no new operating guidance; its substance is the Iridium audited and unaudited financials (incorporated by reference) and the pro forma combined statements.

The pro forma statements show the financing burden clearly. The deal is funded with a $3.6 billion^b 364-day bridge facility at an effective rate of about 8.0%, which the filing says Rocket Lab intends to replace with permanent financing, though terms are not yet determinable. Pro forma combined cash falls to about $1.0 billion from $2.1 billion at June 30, 2026, and pro forma interest expense rises to about $143 million for the six months ended June 30, 2026 and $312 million for FY2025.

On a pro forma basis, Rocket Lab's combined results show a six-month net loss of $154.7 million^c (EPS of -$0.23) and a FY2025 net loss of $203.0 million (EPS of -$0.36), compared with standalone Rocket Lab net losses of $94.3 million and $198.2 million. Pro forma combined revenue is about $879 million for the six months and $1.47 billion for FY2025.

The filing also flags several uncertainties: preliminary purchase price allocation with about $2.2 billion^d of goodwill and $4.3 billion of intangibles (subject to change), a tax-free reorganization treatment that depends on the cash-to-stock mix, a possible reduction in bridge borrowings if Iridium debt amendments are completed, and the acquisition of Aireon by Iridium on July 2, 2026, which adds debt not reflected in these figures. The transaction remains subject to Iridium stockholder approval, regulatory approvals, and the effectiveness of the Form S-4.

02—Key points

Key Highlights

Deal terms: Iridium holders receive $27.00 cash plus Rocket Lab stock; the exchange ratio floats between 0.4000 (VWAP ≤ $67.50) and 0.2400 (VWAP ≥ $112.50), currently 0.3894 at a $69.33 VWAP.
Estimated total purchase consideration is about $7.59 billion, including roughly $2.86 billion in cash, $2.86 billion in stock, $1.77 billion to retire Iridium debt, and $94 million in equity awards.
Financing is a $3.6 billion 364-day bridge facility at an effective rate of about 8.0%, with interest expense of $141 million (six months 2026) and $286 million (FY2025) embedded in the pro forma results.
Pro forma combined net loss is $154.7 million for six months 2026 (EPS -$0.23) and $203.0 million for FY2025 (EPS -$0.36), versus standalone Rocket Lab losses of $94.3 million and $198.2 million.
Pro forma combined revenue is about $879 million for six months 2026 and $1.47 billion for FY2025, combining Rocket Lab's and Iridium's revenue, with Iridium contributing the large majority.
Pro forma cash falls to about $1.0 billion from $2.1 billion, and total assets rise to about $11.8 billion, with goodwill of about $2.5 billion and intangibles of about $4.6 billion.
Purchase accounting is preliminary: the allocation may change materially, the pro forma figures exclude synergies, and additional debt from Iridium's July 2026 Aireon acquisition is not reflected.

03—Questions

Frequently Asked Questions

What will Iridium shareholders receive in the Rocket Lab deal?
Each Iridium share converts into $27.00 in cash plus Rocket Lab common stock at an exchange ratio that depends on Rocket Lab's 10-day VWAP before closing. The ratio is 0.4000 at or below $67.50, 0.2400 at or above $112.50, and $27.00 divided by the VWAP in between. At the $69.33 VWAP used in the filing, the ratio is 0.3894, or about 41.3 million new Rocket Lab shares in total.
How will the transaction be financed, and what does it cost?
The deal relies on a $3.6 billion 364-day bridge facility from Deutsche Bank and Wells Fargo, with an effective rate of about 8.0%. Rocket Lab says it intends to replace it with permanent financing on better terms, but those terms are not yet determinable. Each 0.125% change in the rate moves annual interest expense by about $4.6 million on the full balance.
How does the deal affect Rocket Lab's financial profile?
On a pro forma basis, the combined company shows larger losses than Rocket Lab alone, driven mainly by about $312 million of FY2025 interest expense and about $286 million of amortization and stock compensation. Pro forma EPS is -$0.36 for FY2025 and -$0.23 for six months 2026, and cash drops to roughly $1.0 billion. The filing excludes any expected synergies, so these figures show the financing and accounting effects rather than a forecast of operating performance.
What could still change, and what are the main risks?
The purchase price allocation is preliminary and could change materially, and each $1 move in Rocket Lab's share price above $112.50 changes consideration by about $25 million, while each $1 below $67.50 changes it by about $42 million. The transaction needs Iridium stockholder approval, regulatory clearances, and an effective Form S-4. The tax-free reorganization treatment depends on the cash-to-stock mix, and the bridge borrowings could fall if Iridium debt amendments are completed. Iridium's July 2026 Aireon acquisition added debt that is not in these figures.

04—Continue

← View all 8-K filings